We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+15.28%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
-$394M
Cap. Flow
-$894M
Cap. Flow %
-41.57%
Top 10 Hldgs %
42.88%
Holding
116
New
14
Increased
12
Reduced
29
Closed
26

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$48.4M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$46.1M
3
TSRO
TESARO, Inc.
TSRO
+$22.6M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$21.3M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
XNPT
XENOPORT, INC.
XNPT
+$81.5M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$49.8M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$35.4M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.12%
2 Financials 3.34%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNVA
101
DELISTED
Rennova Health, Inc.
RNVA
– –
-392
Closed -$111K
INNL
102
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
– –
-302,923
Closed -$1.67M
ZLTQ
103
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-1,297,000
Closed -$35.4M
GI
104
DELISTED
EndoChoice Holdings, Inc.
GI
– –
-1,198,950
Closed -$5.88M
CYNA
105
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-48,840
Closed -$818K
RLYP
106
DELISTED
RELYPSA INC COM
RLYP
– –
-1,670,383
Closed -$30.9M
XNPT
107
DELISTED
XENOPORT, INC.
XNPT
– –
-11,572,125
Closed -$81.5M
1 2 3 4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2016 Portfolio in Review

As of Q3 2016, Deerfield Management held 116 positions worth $2.15B, down 15% from $2.54B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Deerfield Management withdrew a net $894M in Q3 2016, closing 26 positions and reducing 29 holdings. Its most notable exit was XENOPORT, INC., an estimated $81.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $56M.

  • Deerfield Management's largest Q3 2016 buy was NEVRO CORP.: 536,355 shares worth $56M.
  • Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q3 2016, an estimated $46.1M increase.
  • Deerfield Management's biggest Q3 2016 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $143M.
  • Deerfield Management fully exited XENOPORT, INC. in Q3 2016, selling an estimated $81.5M.
  • Deerfield Management's ten largest holdings make up 43% of its $2.15B portfolio in Q3 2016.
  • Deerfield Management opened 14 new positions and closed 26 in Q3 2016.
  • Deerfield Management's portfolio value fell 15% quarter-over-quarter to $2.15B.

Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.